Minerva Neurosciences | NERV - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Adma Biologics USD 1.63M 54K 2025-12
ALKERMES USD 12.28M 7.63M 2025-12
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Cipla INR 140.3M 8.5M 2025-12
Compugen USD 954K 116K 2025-09
CSL USD 215M 111M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Grifols EUR 156.07M 31.46M 2025-09
Halozyme Therapeutics USD 4.91M 615K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
J&J USD 18M 290M 2025-09
Merck USD 412M 85M 2025-12
Minerva Neurosciences USD 2.31M 60K 2024-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Novavax USD 5.82M 342K 2025-12
Pfizer USD 711M 59M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR -25M 252M 2025-12
Takeda JPY 123.63B 40.49B 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09